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tGf-β1 increases viral burden and 
promotes HIV-1 latency in primary 
differentiated human bronchial 
epithelial cells
S. chinnapaiyan1, R. K. Dutta1, M. nair1, H. S. chand  1, I. Rahman  2 & H. J. Unwalla1
Combination antiretroviral therapy (cART) has increased the life expectancy of HIV patients. However, 
the incidence of non-AIDS associated lung comorbidities, such as COPD and asthma, and that of 
opportunistic lung infections have become more common among this population. HIV proteins secreted 
by the anatomical HIV reservoirs can have both autocrine and paracrine effects contributing to the HIV-
associated comorbidities. HIV has been recovered from cell-free bronchoalveolar lavage fluid, alveolar 
macrophages, and intrapulmonary lymphocytes. We have recently shown that ex-vivo cultured primary 
bronchial epithelial cells and the bronchial brushings from human subjects express canonical HIV 
receptors CD4, CCR5 and CXCR4 and can be infected with HIV. Together these studies suggest that the 
lung tissue can serve as an important reservoir for HIV. In this report, we show that TGF-β1 promotes 
HIV latency by upregulating a transcriptional repressor BLIMP-1. Furthermore, we identify miR-9-5p as 
an important intermediate in TGF-β-mediated BLIMP-1 upregulation and consequent HIV latency. The 
transcriptionally suppressed HIV can be reactivated by common latency reactivating agents. Together 
our data suggest that in patients with chronic airway diseases, TGF-β can elevate the HIV viral reservoir 
load that could further exacerbate the HIV associated lung comorbidities.
In aging HIV-infected populations, comorbid diseases are important determinants of morbidity and mortality. 
Even in the cART era, HIV patients die of non-AIDS comorbidities almost a decade earlier than their non-HIV 
counterparts1. cART successfully suppresses viral replication but is unable to eradicate HIV due to presence of 
latently infected anatomical reservoirs2,3. As people living with HIV grow older, the long-term effects of low-level 
viral replication and expression of viral proteins from these reservoirs, as well as treatment with cART itself, pro-
motes many of these comorbidities. For instance, HIV Tat, secreted by infected cells, can have pleiotropic effects 
on neighboring cells as well. HIV Tat is an immediate early gene of HIV and its expression is not suppressed by 
antiretrovirals1–4. Lung diseases such as COPD, are emerging as significant comorbidities in the HIV-infected 
population5,6. A large proportion of people living with HIV also smoke tobacco that can exacerbate lung comor-
bidities7. HIV infection is an independent risk factor for the development of COPD even after accounting for 
smoking status8. Increased HIV reservoir load in the lung can exacerbate HIV associated lung comorbidities. 
We have shown that primary human bronchial epithelial cells can be infected with HIV9. The infection kinetics 
demonstrated an early spike in virus release that subsides and reaches a low-level steady state with detectable HIV 
Gag and HIV RNA up to 50 days post-infection (duration of experiment) suggesting that bronchial epithelium 
can serve as HIV reservoirs.
TGF-β is a multifunctional growth factor and it regulates cell growth, adhesion and differentiation in a wide 
variety of cell types10,11. TGF-β isoforms are expressed and secreted by several cell types in the airway, including 
epithelia in association with a latency-associated peptide. This provides a TGF-β reservoir in the extracellular 
matrix12 that participates in normal lung physiological processes and functions in local immunomodulation, 
regulation of cell proliferation and differentiation, as well as the control of normal tissue repair. TGF-β signaling 
is upregulated by HIV Tat, cigarette smoke and in chronic lung diseases like COPD, asthma, pulmonary fibrosis 
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and lung infections13–19. We have previously reported that TGF-β and cigarette smoke suppress miR-141-5p to 
promote CCR5 expression on primary bronchial epithelial cells, which increases viral entry and infection by 
R5-tropic HIV. In this report, we demonstrate that TGF-β signaling downregulates miR-9-5p, thereby increasing 
expression of the transcriptional repressor BLIMP-1, known to promote formation of HIV reservoirs20. We show 
that TGF-β induced BLIMP-1 expression correlates with HIV transcriptional suppression in primary bronchial 
epithelial cells. Taken together with our earlier reports, TGF-β signaling in the airway promotes infection of bron-
chial epithelium and increases the reservoir pool in the airway.
Results
tGf-β promotes HIV latency in NHBE cells. TGF-β signaling alters the bronchial epithelial microR-
NAome21. Several miRNAs are known to directly or indirectly affect HIV replication22. In our earlier report, we 
have identified that cigarette smoke and TGF-β1 increases the expression of CCR5 coreceptor by suppressing 
miR-141-5p that, at least in case of cigarette smoke, increases entry by R5-tropic HIV BaL strain23. Given that 
TGF-β signaling is upregulated by Tat, cigarette smoke and in chronic lung diseases, we tried to determine the 
effects of persistent TGF-β signaling on HIV infection in primary bronchial epithelium redifferentiated ex-vivo. 
NHBE cultures redifferentiated at the ALI were pretreated with recombinant TGF-β1 (10 ng/ml; vehicle as con-
trol). Following sixteen hours of pretreatment (based on our data that effects of TGF-β1 effects changes in miR-
141-5p and CCR5 expression after 16 hours of treatment21), NHBE ALI cultures were infected with 5 ng p24 
equivalent of HIV BaL (R5-tropic strain) as described by us earlier9,23. An additional 16 hours post-infection, cul-
tures were washed apically and basolaterally four times with phosphate buffer saline (PBS). The fourth PBS wash 
was collected as day 0 to confirm that all input virus had been removed. Media was completely replaced every 
48 hours with fresh ALI media with vehicle or TGF-β. A schematic of the treatment regimen is demonstrated in 
Fig. 1a. Poli et al. have demonstrated that acute TGF-β1 treatment interferes with early transcription of HIV in 
U1 cell lines24. To determine if TGF-β1 promotes latency, an identical experimental set was treated with latency 
reactivating agents (LRAs), Bryostatin-2 (10 nM/ ml; Protein kinase C agonist), and HMBA (10 mM/ ml; P-TEFb 
activator) on Day 6. Darcis et al.25, have shown that a combination of prostatin/HMBA followed by Bryostatin-2/
HMBA provides maximal transcriptional reactivation across multiple cells lines tested. However, prostatin also 
downregulates the CCR5 receptor26, which can directly contradict the effects of TGF-β1 mediated CCR5 upreg-
ulation on de-novo HIV infection. Hence, we chose a combination of Bryostatin-2/HMBA as LRAs. The infec-
tions were allowed to proceed up to day 8. Culture supernatants were collected and analyzed for HIV p24. As 
seen in Fig. 1b, TGF-β1 treatment decreases supernatant p24. Addition of LRAs, Bryostatin-2/HMBA to TGF-β1 
treated NHBE cells restores p24 levels. To confirm if this suppression is a consequence of a direct effect on viral 
transcription and not due to indirect effects of the LRAs on cellular co-factors involved in later stages of viral 
replication, total RNA from an identical experiment was isolated and HIV transcripts were quantitated by qRT-
PCR as described by us earlier9. As seen in Fig. 1c, TGF-β1 suppresses viral RNA and this suppression correlates 
with HIV p24 suppression. Addition of HMBA/Bryostatin-2 to HIV BaL infected NHBE cells, not treated with 
TGF-β1, did not demonstrate significant increase in viral RNA or p24 levels. Together these data demonstrate that 
that TGF-β suppresses viral transcription and promotes HIV latency in NHBE ALI cultures. The experimental 
regimen had only a marginal effect on cell viability across all treatments on Day 8 (Supplementary Fig. 2).
Next, we determined whether TGF-β1 increases the number of cells infected by HIV BaL (R5-tropic strain). 
NHBE ALI cultures were treated and reactivated identically. Cultures were fixed and stained with anti-gp120 
antibody as described before27. As seen in Fig. 1d, TGF-β1 suppresses intracellular expression of HIV gp120. 
However, addition of LRAs demonstrates an increase in intensity as well as number of cells stained with 
anti-gp120 antibody. Together, these data suggest that TGF-β1 enhances infection of NHBE ALI cultures but 
suppresses HIV transcription.
tGf-β signaling alters mRNA levels of HIV-1 host restriction factors in NHBE cells. Several 
reports have identified host cellular proteins that serve as anti-HIV restriction factors to block viral entry, nuclear 
import and integration, transcription, translation or budding. We had observed that TGF-β1 suppresses viral 
RNA and this relates well with HIV p24 output in Fig. 1. Given reports by Poli et al., that TGF-β1 suppresses early 
stage of HIV replication24, we tried to determine if TGF-β1 alters expression of cellular HIV restriction factors 
affecting viral entry, proviral DNA integration and transcription. We specifically focused on the expression of 
IFITM3 (virus-endosomal fusion), PSIP1/LEDGF/p75 (HIV integration) and BLIMP-1 (HIV proviral transcrip-
tion). NHBE ALI cultures were treated with recombinant TGF-β1. Total RNA was isolated and mRNA levels of 
IFITM3, PSIP1 and BLIMP-1 were determined by qRT-PCR. As seen in Fig. 2a, TGF-β1 does not affect expres-
sion of IFITM3 but suppresses PSIP1 mRNA (Fig. 2b) and increases mRNA expression of BLIMP-1 (Fig. 2c), 
compared to vehicle treated controls.
Changes in PSIP1 and BLIMP-1 mRNA levels manifest as decreases in protein levels. Next, we 
tried to determine if TGF-β induced changes in BLIMP-1 and PSIP1 mRNA translates to changes in their protein 
levels as well. NHBE ALI cultures were treated with TGF-β1. 48 hours post-treatment, total protein was iso-
lated and quantified by western blot analysis for BLIMP-1 and PSIP1 expression. We found that TGF-β mediated 
changes in mRNA expression of BLIMP-1 and PSIP1 translates to corresponding changes in protein levels as well. 
TGF-β signaling significantly upregulates BLIMP-1 protein levels (Fig. 3a) and suppresses PSIP1 levels (Fig. 3b) 
compared to vehicle treated controls. Next we tried to determine if suppression of PSIP1 translates to decreased 
proviral integration. NHBE ALI cultures were treated with recombinant TGF-β1 (or vehicle as control). Sixteen 
hours post-treatment NHBE ALI cultures were infected with 5 ng p24 equivalent of HIV BaL, and the infection 
was allowed to proceed for an additional 24 hours. Experiments were terminated and genomic DNA was used to 
quantitate integrated HIV proviral DNA as first demonstrated by Brussel and Sonigo28 and later adapted by us9. 
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As seen in Fig. 3c, TGF-β1 mediated suppression of PSIP1 does not result in decreased viral integration, suggest-
ing that the magnitude of TGF-β mediated PSIP1 suppression is not sufficient to affect viral integration. On the 
contrary, TGF-β1 significantly increases the number of integrated provirus in NHBE ALI cultures.
BLIMP-1 and Histone deacetyl transferases are involved in TGF-β induced latency in the bron-
chial epithelium. BLIMP-1 is a transcriptional repressor that can potentially suppress HIV transcription 
via multiple pathways. Indeed BLIMP-1 has been shown to directly bind HIV LTR20. However, BLIMP-1 has 
also been shown to mediate transcriptional repression via HDAC recruitment29 and suppression of transcription 
factors like Myc, which can indirectly impact HIV transcription30. This is further complicated by reports that 
BLIMP-1 itself is regulated by HDACs31 and HDAC inhibitors suppress BLIMP-132. BLIMP-1 has been shown to 
directly activate 93 different genes and directly suppresses 121 target genes. Of these, BLIMP-1 activated 7 and 
repressed 13 transcription factors, any of which may impact viral transcription33. To determine if the effects of 
TGF-β1 mediated suppression is a consequence of direct binding of BLIMP-1 to HIV LTR, we performed a chro-
matin immunoprecipitation assay (CHIP) as described20. NHBE ALI cultures were pretreated with TGF-β1 and 
infected with 5 ng p24 equivalent of HIV BaL as mentioned in Fig. 1. Eight days post-infection, chromatin was 
Figure 1. TGF-β1 promotes HIV latency in NHBE cells. (a) Experimental timeline for effect of TGF-β1 on 
HIV infection. (b) NHBE cultures redifferentiated at the ALI were treated and infected as shown in (a). Culture 
supernatants were collected on day 8 for post-reactivation p24 analysis using p24 ELISA kit. (c) Total RNA was 
isolated and HIV transcripts were quantitated by qRT-PCR. TGF-β1 treatment suppresses HIV mRNA and this 
can be reversed with the combination of LRAs Bryostatin-2 and HMBA. TGF-β1 suppresses viral p24 and this 
corelates well with mRNA suppression. n = NHBE ALI cultures from at least 5 different lungs; *p < 0.05. (d) The 
TGF-β-mediated suppression of gp120 expression levels in HIV-infected and latency reactivated NHBEs, scale – 
10 µ. n = NHBE ALI cultures from 3 different lungs, *p < 0.05).
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prepared and protein-DNA complexes were precipitated and enriched with Blimp-1-specific antibody. Michaels 
et al.20, have reported BLIMP-1 binding at +142/+237 ISRE site in HIV LTR. Figure 4a shows that TGF-β1 treat-
ment significantly increases BLIMP-1 mobilization at this site in NHBE ALI cultures infected with HIV BaL. 
BLIMP-1 has been shown to mediate its effects via recruitment of histone deacetylases29. Moreover BLIMP-1 
itself is epigenetically regulated31,32. NHBE ALI cultures were treated similar to that in Fig. 1a. On day 6, the 
HDAC inhibitor vorinostat (1 μM) was added to the cultures. Vorinostat restores HIV transcription in TGF-β1 
treated cells and this is reflected in viral p24 levels identifying the role of HDACs in TGF-β1 induced HIV latency 
(Fig. 4b,c). Surprisingly we observed that vorinostat also increased HIV output in TGF-β1 untreated (vehicle 
treated) NHBE ALI cultures suggesting that there is baseline suppression of HIV transcription in primary bron-
chial epithelial cells by HDACs. Hence primary bronchial epithelium can serve as HIV reservoirs and this is 
exacerbated by TGF-β1 signaling.
Figure 2. TGF-β signaling alters mRNA expression of HIV-1 host restriction factors in NHBE cells. NHBE ALI 
cultures were treated with recombinant TGF-β1 (10 ng/ml; vehicle as control). 48 hours post-treatment, total 
RNA was isolated and mRNA levels of IFITM3, PSIP1 and BLIMP-1 were determined by qRT-PCR. (a) TGF-
β1 does not alter expression of IFITM3 mRNA. (b) TGF-β1 suppresses PSIP1 mRNA. (c) TGF-β1 increases 
mRNA levels of BLIMP-1 compared to vehicle treated controls. n = NHBE ALI cultures from 3 different lungs; 
*significant (p < 0.05).
Figure 3. TGF-β1 alters the protein expression of HIV-1 restriction factors such as BLIMP-1 and PSIP-1 in 
NHBE cells. NHBE ALI cultures were treated with recombinant TGF-β1 (or vehicle as control). 48 hours post-
treatment, total protein was isolated and quantified by western blot analysis. (a) BLIMP-1 protein levels were 
significantly higher in TGF-β1 treated NHBE ALI cultures compared to vehicle treated controls. (b) TGF-β1 
suppresses PSIP-1 protein levels in NHBE ALI cultures compared to vehicle treated controls. (c) TGF-β1 
treatment demonstrates increased HIV integration events in NHBE cells. NHBE ALI cultures were treated with 
recombinant TGF-β1 (or vehicle as control). 16 hours post-treatment NHBE ALI cultures were infected with 
5 ng p24 equivalent of HIV BaL (R5-tropic strain) and the infection was allowed to proceed for an additional 
24 hours. Experiments were terminated and genomic DNA was isolated and used to quantitate integrated HIV 
proviral DNA. n = NHBE ALI cultures from 3 different lungs; *significant (p < 0.05). L = Lung number.
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tGf-β1 upregulates BLIMP-1 by suppressing miR-9-5p. TGF-β signaling has been shown to alter 
miRNA homeostasis34,35. In our previous report, we have demonstrated that TGF-β suppresses miR-141-5p to 
increase expression of CCR5 receptor. We tried to determine if TGF-β mediated BLIMP-1 upregulation is a con-
sequence of miRNA mediated regulation. Analysis of literature revealed a potential link between TGF-β signal-
ing, miR-9-5p and BLIMP-1. miR-9-5p has been shown to regulate BLIMP-136,37, while TGF-β has been shown to 
epigenetically suppress miR-9-5p expression38. In our recent report, a microRNAome analysis of TGF-β1 treated 
NHBE ALI cultures demonstrated a Log2 fold suppression of −4.45 in expression of miR-9-5p39. We used a sys-
tematic approach to identify the role of miR-9-5p in TGF-β mediated BLIMP-1 upregulation.
We first tried to validate our miRNA array data to determine if TGF-β suppresses miR-9-5p in primary bron-
chial epithelial cells. NHBE ALI cultures were treated with recombinant TGF-β1 (vehicle as control). As seen in 
Fig. 5a, TGF-β1 completely abrogates miR-9-5p expression in NHBE ALI cultures. Next, we tried to determine if 
miR-9-5p suppresses BLIMP-1. For these experiments, we used transient transfection of the miR-9-5p mimic in 
BEAS-2B airway epithelial cells. This is because BEAS-2B cells are readily transfected with a higher transfection 
efficiency compared to primary bronchial epithelial cells. BEAS-2B airway epithelial cells were transfected with 
miR-9-5p mimic (20 nM) using lipofectamine RNAiMAX according to manufacturer’s instructions. Forty-eight 
hours post-transfection, total RNA was isolated and quantitated for BLIMP-1 expression. As seen in Fig. 5b, miR-
9-5p mimic suppresses BLIMP-1 mRNA. Next, we tried to determine if miR-9-5p mimics can reverse TGF-β 
Figure 4. TGF-β1 mediates HIV suppression via BLIMP-1 and histone deacetylases. NHBE ALI cultures were 
treated with TGF-β1 or vehicle and infected similar to that in Fig. 1a. Chromatin was isolated on Day 3 and 
BLIMP-1 mobilization to HIV LTR was determined using CHIP. TGF-β1 increases mobilization of BLIMP-1 to 
HIV LTR (a). n = NHBE ALI cultures from 4 different lungs; *significant (p < 0.05). Another set was TGF-β1 
treated and infected identically, On day 6 the HDAC inhibitor vorinostat (1 μM) was added. On day 8 culture 
supernatants were collected and analyzed for HIV p24 (b). Total RNA was isolated and analyzed for HIV LTR 
using qRT-PCR (c). TGF-β1 mediated HIV transcriptional suppression can be restored by HDACi suggesting 
a role of histone deacetylases in TGF-β1 mediated HIV latency. n = NHBE ALI cultures from 5 different lungs; 
*significant (p < 0.05).
Figure 5. TGF-β1 upregulates BLIMP-1 by suppressing miR-9-5p. NHBE ALI cultures were treated with 
recombinant TGF-β1 (or vehicle as control). (a) TGF-β1 completely abolishes miR-9-5p expression in NHBE 
ALI cultures compared vehicle treated control. n = NHBE ALI cultures from three different lungs. (b) BEAS-2B 
airway epithelial cells were transfected with miR-9-5p mimic (20 nM) using lipofectamine RNAiMAX 
according to manufacturer’s instructions. 48 hours post-transfection, total RNA was isolated and quantitated for 
BLIMP-1 expression. The miR-9-5p mimic suppress BLIMP-1 mRNA compared to lipofectamine RNAiMAX 
alone treated cells. n = 3 different experiments using BEAS-2B cells. (c) BEAS-2B airway epithelial were 
transfected with miR-9-5p mimic (20 nM) using lipofectamine RNAiMAX (or lipofectamine RNAiMAX as 
control). 24 hours following transfection, cells were treated with recombinant TGF-β1. 16 hours following TGF-
β1 treatment, total RNA was isolated and quantitated for BLIMP-1 expression. The TGF-β1 increases BLIMP-1 
expression and this increase is reversed in cells transfected with miR-9-5p mimic. n = 3 different experiments 
using BEAS2B cells. *significant (p < 0.05).
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mediated BLIMP-1 upregulation. BEAS-2B airway epithelial were transfected with miR-9-5p mimic (20 nM) 
using lipofectamine RNAiMAX. 24 hours following transfection, cells were treated with recombinant TGF-β1. 
Lipofectamine RNAiMAX was added to the control set and was also included in the TGF-β1 treated set. Sixteen 
hours following TGF-β1 treatment, total RNA was isolated and quantitated for BLIMP-1 expression. As seen in 
Fig. 5c, TGF-β signaling increases BLIMP-1 expression and this increase is reversed in cells transfected with miR-
9-5p mimic.
Discussion
HIV infection is linked with a greater incidence of pulmonary diseases normally associated with aging and their 
presentation at younger ages. cART cannot eradicate HIV due to the presence of HIV reservoirs in different 
anatomical sites40. Persistent low-level viral replication coupled with expression of viral proteins not controlled 
by antiretrovirals are the principal causes of non-AIDS comorbidities in people living with HIV41,42. The onset 
and severity of these comorbidities can correlate with the viral reservoir load43. Airway diseases like chronic 
bronchitis, pneumonia, asthma and COPD are principal non-AIDS HIV associated comorbidities in people liv-
ing with HIV. In our previous studies, we first demonstrated that the bronchial epithelium expresses canonical 
HIV receptors CD4, CCR5 and CXCR4 and can be infected by both R5 and X4 tropic HIV. Several reports have 
shown that TGF-β can have contradictory effects on HIV transcription in different cell types44,45 while also hav-
ing contradictory effects on different pathways of HIV activation. For instance, TGF-β suppresses PMA induced 
activation but not TNF-α induced activation of HIV LTR24. Given that, TGF-β signaling is increased in smokers 
and chronic airway diseases, we tried to determine the effects of increased TGF-β signaling on HIV infection. In 
our previous report we have shown that HIV output spikes initially followed by a gradual decrease that reaches 
steady state around Day 89. To disentangle the effects of HIV suppression by TGF-β1 from the normal kinetics 
of decreasing viral output observed in NHBE cells, we chose addition of LRAs on day 6 followed by culture 
supernatant p24 readout on day 8. Our data demonstrate that TGF-β treatment suppresses HIV RNA, which 
manifests as decreased viral output and this can be reversed by some of the common latency reactivating agents. 
While our earlier manuscript reported some cell death around Day 6 which is exacerbated by Day 12, this was 
observed using the RGH-WT virus which is env negative and expresses GFP. The virus was packaged in in vitro 
transient transfections of HEK293 cells with the virus plasmid DNA and either the R5 or X4 tropic HIV envelope. 
Given that this was a single cycle infection we had also used a higher dose for infection (10 ngs p24 equivalent 
compared to 5 ng used in the current study). Our experimental design did not significantly affect cell viability on 
day 8 across all treatments. Transcriptional suppression is considered one of the principal mechanisms of HIV 
latency46,47.
Next, we analyzed the effect of TGF-β signaling on some of the common cellular restriction factors that 
affect viral entry, integration and transcription. Our data showed that TGF-β alters the expression of two of the 
restriction factors tested. TGF-β1 decreases PSIP1 mRNA and protein levels, involved in viral integration, and 
increases the expression of BLIMP-1, a transcriptional repressor known to facilitate HIV latency. To determine 
if decreased HIV RNA and p24 levels were a consequence of decreased integration or suppressed transcription 
or both, we quantitated the integrated proviral DNA in cells treated with TGF-β. Our data (Fig. 3c) showed that 
TGF-β treated NHBE cultures demonstrated increased integration events suggesting that the magnitude of PSIP1 
suppression is not sufficient to observe discernible effects on viral integration. Moreover, increased proviral DNA 
could also be a consequence of increased viral entry on account of CCR5 upregulation. Our data agree with prior 
observations that even a 90% suppression of PSIP1 using RNA interference had only modest effects on viral infec-
tivity48,49 while only a complete knockdown blocks viral integration50. Interestingly, the magnitude of increase 
in integrated copies correlates very well to increase in viral entry by cigarette smoke mediated upregulation of 
CCR5 and consequently HIV entry in cigarette smoke exposed NHBE ALI cultures28. BLIMP-1 expression is 
increased in chronically infected HIV patients and correlates with enhanced expression of negative regulators of 
T cell activation including PD-1, LAG3 and CTLA-4, and with T cell exhaustion and apoptosis36,51. Furthermore, 
the HIV-1 long terminal repeat (LTR) includes binding sites for BLIMP-152. While it is possible that being a 
master regulator of transcription, BLIMP-1 could also mediate its effects indirectly as a consequence of altered 
expression of cellular cofactors. Our data demonstrates that TGF-β1 mediates HIV latency at least in part due to a 
direct mobilization of BLIMP-1 to the HIV LTR. Moreover, Vorinostat can restore TGF-β1 mediated HIV latency 
suggesting that BLIMP-1 may be mediating its effects via histone deacetylases.
We have shown that TGF-β1 alters the bronchial epithelial microRNAome21 Other reports have also shown 
that TGF-β signaling alters miRNA homeostasis in different cell types34,35. We recently reported that TGF-β sig-
naling suppresses the expression of miR-9-5p21. A number of reports in literature identified miR-9-5p as one 
of the miRNAs regulating BLIMP-136,37. Likewise, miR-9-5p and TGFβ are also involved in an autoregulatory 
feedback loop where miR-9-5p inhibits TGF-β signaling and vice versa38. As a pilot experiment, we revisited our 
RNA samples from TGF-β treated cells to determine levels of miR-9-5p. As seen in Fig. 5a, TGF-β treated NHBE 
ALI cultures demonstrated a complete abrogation of miR-9-5p expression. Next, we confirmed that miR-9-5p 
suppresses BLIMP-1 expression and miR-9-5p mimics can reverse the effects of TGF-β1 on BLIMP-1 mRNA 
(Fig. 5b,c), thereby confirming that TGF-β1 suppresses miR-9-5p to upregulate its target BLIMP-1. This also 
provides proof-of-concept that miR-9-5p antagomiRs can be used to modulate TGF-β signaling in the airways 
and reverse TGF-β induced HIV latency in the airway. While our data has explored HIV latency in bronchial 
epithelial cells, it is possible that TGF-β increases viral reservoirs in other cell types in the lung like alveolar mac-
rophages by a similar mechanism.
In conclusion, we report for the first time that TGF-β1 altered bronchial epithelial microRNAome has a 
paradoxical effect on HIV infection of the bronchial epithelial cells resulting in an increased infection, while 
also promoting HIV latency. The mechanism is summarized in Fig. 6. TGF-β1 induced miR-141-5p increases 
CCR5 expression leading to an increased infection of airway epithelial cells while TGF-β1 induced miR-9-5p 
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suppression upregulates BLIMP-1, which in turn suppresses viral transcription. The net effect of these actions will 
increase viral load while also promoting HIV latency. Inflammation during disease exacerbations will reactivate 
HIV transcription, consequently increasing the levels of HIV proteins in the airway. We and others, have already 
demonstrated that HIV proteins Tat and gp120 can affect components of the mucociliary clearance apparatus 
as well as epithelial barrier integrity9. Hence, increased viral load and in the airway will further exacerbate lung 
comorbidities in people living with HIV. Moreover, miR-9-5p might represent a promising and potentially novel 
biomarker as an index of TGF-β signaling and HIV viral load in the lungs and overall airway health in people 
living with HIV.
Materials and Methods
Cell culture. Primary normal human bronchial epithelial (NHBE) cells were obtained from properly con-
sented donors whose lungs were not suitable for transplantation for the causes unrelated to airway complications 
and supplied by University of Miami Life Alliance Organ Recovery Agency (LAORA). Since the material was 
obtained from deceased individuals with minor, de-identified information, its use does not constitute human sub-
jects research as defined by CFR 46.102. A signed and well-documented consent of everyone (or legal healthcare 
proxy) for donation of lungs for research purpose is on file with the LAORA and allows research purpose of this 
material. NHBE cells were isolated and re-differentiated at the air-liquid interface (ALI) cultures as described by 
Fulcher and Randall53,54 and adapted by us55,56. These primary cultures undergo differentiation at the ALI repro-
ducing both the in vivo morphology and key physiologic processes to regenerate the native bronchial epithelium 
ex vivo53,54. Transformed human bronchial epithelial cell line BEAS-2B cells (CRL-9609, American Type Culture 
Collection ATCC, Manassas, VA, USA) were grown as monolayers at 5% CO2 at 37 °C in serum-free defined 
BEGM growth medium according to the supplier’s instructions.
Virus strains and infection studies. The R5-tropic viral strain HIV BaL was a kind gift from Dr. 
Madhavan Nair (Department of Immunology and Nano-Medicine, Institute of Neuroimmune Pharmacology, 
Herbert Wertheim College of Medicine, Florida International University. Miami, FL). NHBE ALI cultures were 
infected apically and basolaterally with 5 ng p24 equivalent of R5-tropic HIV strain (BaL) as described earlier9. 
16 hours post-infection, cells were washed apically and basolaterally with PBS four times to remove any residual 
input virus. The fourth wash was collected for p24 analysis and measured as day 0 to confirm that all input virus 
had been removed. Culture media was changed every 48 hours and media collected on Day 8 was used for p24 
antigen analysis using p24 ELISA kit (ZeptoMetrix Corp. Cat # 0801200) according to manufacturer’s protocol.
RNA isolation and quantitative real-time PCR (qRT-PCR). To examine mRNA expression, total 
RNA was extracted using the Qiagen RNeasy mini kit (Cat # 74104) and complementary DNA (cDNA) was 
reverse transcribed using the Applied Biosystems high-capacity cDNA reverse transcription kit (Cat # 
4368814). qRT-PCR was performed on the Bio-Rad CFX96 real-time system using validated TaqMan probes 
(Life Technologies/Applied Biosystems HIV-LTR, Cat # Pa03453409_s1; IFITM3, Cat # Hs03057129_s1; BST2, 
Cat # Hs01561315_m1; BLIMP-1, Cat # Hs00153357_m1; PSIP1, Cat # Hs01045711_g1; and GAPDH, Cat # 
Hs02786624_g1). qRT-PCR results are represented as relative quantification normalized against internal control 
(GAPDH).
Figure 6. TGF-β1 increases HIV reservoir load in the bronchial epithelium. Schematic representation of the 
effects of TGF-β1 on host restriction factors to promote the HIV-1 reservoir load in human bronchial epithelial 
cells. TGF-β1 increases levels of canonical HIV receptor CCR5. This increases infection of bronchial epithelium 
by R5-tropic HIV leading to an increased number of integrated HIV DNA. TGF-β1 also suppresses miR-9-5p 
with a consequent upregulation of its target transcriptional repressor BLIMP-1. Together this leads to increased 
infection events and latency thereby increasing the viral load in the airway.
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Detection of HIV proviral DNA. TGF-β1 (10 ng/ ml) treated with NHBE ALI cultures (vehicle as control) 
reported by us earlier56, it was purchased from the Life Technologies (Cat # PHG9214) and 16 hours post-treated 
cells were infected with 5 ng of HIV BaL (R5-tropic strain) HIV as described by us earlier9 and cells were washed 
with phosphate buffer saline (PBS) four times after 16 hours post-infection. After 24 hours, genomic DNA was 
extracted using the Wizard SV genomic DNA purification system (Promega, Cat# A2360) according to the man-
ufacturer’s protocol. U937 cells (aidsreagent catalog # 165), stably infected with R5-tropic HIV, was used as inte-
grated HIV DNA standard to generate the standard curve. HIV integration in NHBE ALI cultures was determined 
using comparative Ct method by 2-step qPCR method described by Brussel and Sonigo28 and adapted by us9. Cell 
equivalent was determined using the DNA copy number and dilution calculator (Thermofisher Scientific) based 
on amount of input DNA from infected NHBE ALI cultures and data was expressed as copies/cell.
Western blot analysis and antibodies. Whole-cell lysates were prepared by washing cells with PBS and 
lysing them with radioimmunoprecipitation assay (RIPA) buffer (ThermoFisher Scientific, Cat # 89901) along 
with protease inhibitor cocktail (ThermoFisher Scientific, Cat # 78410). Protein was measured using the Bio-Rad 
protein assay dye reagent (Bio-Rad, Cat # 5000006) according to manufacturer directions. Briefly, each protein 
sample (50 µg) was subjected to heat denaturation at 100 °C for 5 minutes before loading onto a 4 to 20% gel and 
run at 100 V. Protein was transferred to PVDF membrane. Following blocking in 5% milk primary antibod-
ies; BLIMP-1 (1:1000; Cell Signaling, Cat # 9115), PSIP1 (LEDGF/p75; 1:1000 Cell Signaling, Cat # 2088) or 
α-tubulin (1:1000; Cell Signaling, Cat # 2125) were added. Blot was incubated in an anti-rabbit secondary anti-
body diluted to a concentration of 1:2500. Bands were detected in Chemidoc (Bio-Rad Laboratories, USA) using 
supersignal west femto maximum sensitivity substrate (ThermoFisher Scientific, Cat # 34095) in accordance with 
the manufacturer’s instruction. Quantitative densitometry analyses were performed using the Quantity One soft-
ware (Bio-Rad Laboratories, USA) and the density values are normalized to α-tubulin.
Chromatin immunoprecipitations (ChIP)- qPCR. NHBE ALI cultures were treated with TGF-β1 
(10 ng/ml; vehicle as control). 16 hours of post-treatment cultures were infected with HIV BaL as described 
by us earlier9,23. An additional 16 hours post-infection, cultures were washed apically and basolaterally four 
times with phosphate buffer saline (PBS) and this was considered Day 0. Day 3 post-infection cells were har-
vested and ChIP assay was performed using the ChromaFlash High-Sensitivity ChIP kit (Epigentek, Cat # 
P-2027) according to the manufacturer’s instructions. Chromatin samples were immunoprecipitated using 
anti-BLIMP-1 antibody (ChIP Grade, Abcam, Cat # ab13700). qPCR analyses were performed using EpiQuik 
Quantitative PCR Fast kit (Epigentek, Cat # P-1029) with primers 5′- TCCCTCAGACCCTTTTAGTCAG-3′ 
and 5′-GTCGAGAGAGCTCCTCTGGTTT-3′ flanking the +142 F/+237 R region of HIV-1 LTR reported by 
Michaels et al.,20. Data were analyzed as described by Natarajan et al.,57.
miR-9-5p mRNA expression analysis by qRT-PCR. NHBE ALI cultures were treated with TGF-β1 
(vehicle as control) as described above. Following 16 hours total RNA was isolated from control and TGF-β 
treated with NHBE ALI cultures by using the Qiagen RNeasy mini kit (Cat # 74104) and cDNA was reverse tran-
scribed by the Applied Biosystems TaqMan™ Advanced miRNA cDNA synthesis kit (Life Technologies/Applied 
Biosystems, Cat # A28007) according to the manufacturer’s instruction. qRT-PCR was done using TaqMan™ 
fast advanced master mix (Life Technologies/Applied Biosystems, Cat # 4444557) in combination with validated 
TaqMan probes (Life Technologies/Applied Biosystems, hsa-miR-9-5p, Cat # A25576, 478214_mir) according 
to the manufacturer’s directions. qRT-PCR results are represented as relative quantification normalized against 
internal control (GAPDH).
Transfection of miR-9-5p mimics in BEAS-2B cells. BEAS-2B cells were transfected with 20 nM of 
miR-9-5p mimics (Integrated DNA Technologies, Coralville, Iowa, USA) using lipofectamine® RNAiMAX 
transfection reagent (ThermoFisher Scientific, Cat # 13778075) and Opti-MEMTM reduced-serum medium 
(ThermoFisher Scientific, Cat # 31985062) according to manufacturer’s instruction. 24 hours post-transfection, 
cells were treated with TGF-β1 (10 ng/ml) and harvested 16 hours after treatment to quantify mRNA expression 
by qRT-PCR analysis.
Statistical analysis. Unless otherwise mentioned, data were expressed as mean ± SEM from NHBE ALI cul-
tures from at least three lungs. Statistical analysis was carried out and the data were subjected to statistical analysis 
using unpaired t-tests for two groups or ANOVA followed by Tukey Kramer honestly significant difference test 
for multiple comparisons as appropriate. Values of P < 0.05 were considered significant.
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